Kiniksa Pharmaceuticals International (KNSA) Net Equity Issued and Repurchased (2018 - 2020)

Kiniksa Pharmaceuticals International (KNSA) has reported Net Equity Issued and Repurchased for 3 consecutive years, with $118.1 million the latest figure, recorded in Q3 2020.

• For the quarter ending Q3 2020, Net Equity Issued and Repurchased changed N/A year-over-year to $118.1 million; the trailing twelve-month figure through Dec 2020 stood at $118.1 million (up 143.08% YoY), and the FY2020 full-year result was $165.7 million, up 241.03% from the prior year.
• Net Equity Issued and Repurchased rose to $118.1 million in Q3 2020 per KNSA's latest filing, from $48.6 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $190.8 million in Q1 2018 and bottomed at $48.6 million in Q1 2019.
• Historically, Net Equity Issued and Repurchased has averaged $119.2 million across 3 years, with a median of $118.1 million in 2020.
• The widest YoY moves for Net Equity Issued and Repurchased: up 74.53% in 2019, down 74.53% in 2019.
• Over 3 years, Net Equity Issued and Repurchased stood at $190.8 million in 2018, then tumbled by 74.53% to $48.6 million in 2019, then jumped by 143.08% to $118.1 million in 2020.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $118.1 million, $48.6 million, and $190.8 million for Q3 2020, Q1 2019, and Q1 2018 respectively.